This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Université De Poitiers, University of Exeter. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2019
Title: Romain Clement: Innovator in Dyslipidemia Treatment
Introduction
Romain Clement is a notable inventor based in Poitiers, France. He has made significant contributions to the field of medicine, particularly in the prevention and treatment of dyslipidemias. His innovative work focuses on the use of specific compounds to address metabolic disorders.
Latest Patents
Romain Clement holds a patent for "Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias." This invention relates to the use of compounds aimed at preventing and treating dyslipidemia, which is often associated with an excess of fatty acids and sterols in biological membranes. The patent outlines the potential applications of these compounds in pharmaceutical compositions and food supplements, particularly for conditions like metabolic syndrome, type 2 diabetes mellitus, and hepatic steatosis. He has 1 patent to his name.
Career Highlights
Throughout his career, Romain Clement has worked with esteemed institutions such as the Centre National de la Recherche Scientifique and the Université de Poitiers. His research has contributed to advancements in medical treatments and has garnered attention in the scientific community.
Collaborations
Romain has collaborated with notable colleagues, including Miroslava Spanova and Thierry Ferreira. Their joint efforts have furthered research in the field of dyslipidemia and metabolic disorders.
Conclusion
Romain Clement's innovative work in the treatment of dyslipidemia showcases his dedication to advancing medical science. His contributions are vital in addressing significant health issues related to metabolic disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile